Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Sildenafil for Treatment of Digital Ulcers in Patients With Systemic Sclerosis (Sildenafil)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00624273
Recruitment Status : Completed
First Posted : February 27, 2008
Last Update Posted : January 7, 2009
Information provided by:
Charite University, Berlin, Germany

Brief Summary:
This is a pilot study analyzing the effect of sildenafil therapy on digital ulcers in systemic sclerosis. We want to analyze ulcer healing by measuring the size of digital ulcers and their count and analyze the effect of sildenafil on angiography.

Condition or disease Intervention/treatment Phase
Active Digital Ulcers Drug: Sildenafil therapy Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect of Sildenafil on Digital Ulcers in Systemic Sclerosis
Study Start Date : February 2004
Actual Primary Completion Date : November 2004
Actual Study Completion Date : February 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Scleroderma

Arm Intervention/treatment
1, active ulcers
sildenafil treatment
Drug: Sildenafil therapy
oral use
Other Name: start at 25 mg

Primary Outcome Measures :
  1. healing of digital ulcer [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Decrease of frequency/duration of Raynaud's attacks (monthly) [ Time Frame: 6 months ]
  2. Prevention of necroses manifestations [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Digital gangrene, ulcers in patients with severe secondary Raynaud's phenomenon
  2. Stable therapy with vasoactive drugs, such as calcium channel blockers, angiotensin inhibitors/AT II receptor antagonists or pentoxifyllin 4 weeks before and during the treatment with sildenafil.
  3. Unchanged immunosuppressive therapy 3 months before treatment with sildenafil
  4. No effect of prostacyclin treatment, contraindications for prostacyclins, or other reasons excluding this therapy

Exclusion Criteria:

  1. Therapy with iloprost during the last 4 weeks
  2. Sympathectomy during the last 4 weeks
  3. TIA, stroke, myocardial infarction during the last 6 months
  4. Instable angina pectoris
  5. Hemorrhagic diathesis, thrombocytic dysfunction, fibromuscular dysplasia
  6. Microangiopathic hemolytic anaemia
  7. Azotaemia
  8. Hypertonus not adjustable with diuretic, clonidine, ACE inhibitors/AT II antagonists, calcium channel blockers)
  9. Left ventricular ejection fraction< 20%
  10. Hypotonus < 80/40 mm Hg
  11. Positive pregnancy test
  12. History of cancer
  13. History of gastric/duodenic ulcers without endoscopic proof of complete healing
  14. Participation in other studies (currently or during the last 4 weeks)
  15. Abuse of alcohol or other drugs, smoker
  16. Cardiac failure, use of nitrates

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00624273

Layout table for location information
Riemekasten, PD Dr. med.
Berlin, Germany, 10117
Sponsors and Collaborators
Charite University, Berlin, Germany
Layout table for investigator information
Principal Investigator: Dr. Gabriela Riemekasten, MD Charité Universitätsklinik Berlin
Layout table for additonal information
Responsible Party: PD Dr. Gabriela Riemekasten, Charité Universitäsmedizin Identifier: NCT00624273    
Other Study ID Numbers: SDN-D-002G
First Posted: February 27, 2008    Key Record Dates
Last Update Posted: January 7, 2009
Last Verified: July 2003
Keywords provided by Charite University, Berlin, Germany:
digital ulcers,
systemic sclerosis,
vasoactive therapies
Additional relevant MeSH terms:
Layout table for MeSH terms
Scleroderma, Systemic
Scleroderma, Diffuse
Skin Ulcer
Pathologic Processes
Connective Tissue Diseases
Skin Diseases
Sildenafil Citrate
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents